Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $996.00. The company’s shares closed yesterday ...

The company also said it had appointed appointed Ultimate Fighting Championship CEO Dana White, an ally of US president-elect Donald Trump, as one of three new board members. Zuckerberg appears to ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth ... Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $997.00. Discover outperforming stocks and ...

Eli Lilly said it now expects full-year 2024 revenue of about $45 billion. That's lower than the $45.4 billion to $46 billion the company anticipated in October. The new outlook would still mark a ...

and J&J's acquisition appeared to boost the sentiment for M&A in the new year, especially under a likely deal-friendly Trump administration. Eli Lilly said Monday it would acquire an ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...